Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

14.75USD
15 Dec 2017
Change (% chg)

-- (--)
Prev Close
$14.75
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
55,357
52-wk High
$15.95
52-wk Low
$5.50

Latest Key Developments (Source: Significant Developments)

Stemline Therapeutics reports Q3 loss per share $0.68
Thursday, 9 Nov 2017 04:01pm EST 

Nov 9 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports third quarter 2017 financial results.Q3 loss per share $0.68.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Stemline Therapeutics-‍stemline ended Q3 of 2017 with $79.9 million in cash, cash equivalents and investments, as compared to $93.2 million as of June 30, 2017​.  Full Article

Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 has met its primary endpoint​
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics Inc - ‍phase 2 trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm has met its primary endpoint​.Stemline Therapeutics Inc - ‍based on feedback from U.S. FDA, co remains on track to begin submission of BLA in 4Q17-1Q18 timeframe for SL-401​.  Full Article

Stemline Therapeutics files for mixed shelf offering of up to $175 mln
Tuesday, 8 Aug 2017 05:44pm EDT 

Aug 8 (Reuters) - Stemline Therapeutics Inc ::Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​.  Full Article

Stemline Therapeutics Q2 loss per share $0.66
Tuesday, 8 Aug 2017 07:00am EDT 

Aug 8 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics reports second quarter 2017 financial results.Q2 loss per share $0.66.Q2 earnings per share view $-0.48 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial
Thursday, 18 May 2017 07:30am EDT 

May 18 (Reuters) - Stemline Therapeutics Inc :Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting.  Full Article

Stemline Therapeutics Q1 loss per share $0.67
Wednesday, 10 May 2017 05:13pm EDT 

May 10 (Reuters) - Stemline Therapeutics Inc ::Stemline therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.67.Q1 earnings per share view $-0.47 -- Thomson Reuters I/B/E/S.  Full Article

Stemline Therapeutics prices $45 mln public offering of common stock
Friday, 20 Jan 2017 09:00am EST 

Stemline Therapeutics Inc : Stemline Therapeutics prices $45 million public offering of common stock . Says public offering of 4.50 million common shares priced at $10.00per share .Offering is expected to close on January 25, 2017.  Full Article

Stemline Therapeutics announces proposed public offering of common stock
Thursday, 19 Jan 2017 04:04pm EST 

Stemline Therapeutics Inc : Stemline Therapeutics announces proposed public offering of common stock .Stemline Therapeutics Inc says intends to use net proceeds from public offering for clinical, regulatory, manufacturing, among others.  Full Article

Stemline Therapeutics reports oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno)
Monday, 21 Nov 2016 07:30am EST 

Stemline Therapeutics Inc : Stemline Therapeutics Inc- sl-701 was found to be safe and well-tolerated . Stemline Therapeutics Inc- additional clinical data updates are expected next year .Press release - Stemline Therapeutics announces oral presentation of sl-701 phase 2 data in second-line glioblastoma at the 21st annual meeting of the society of neuro-oncology (sno).  Full Article

Stemline Therapeutics Q2 loss per share $0.52
Thursday, 4 Aug 2016 07:59am EDT 

Stemline Therapeutics Inc : Q2 loss per share $0.52 . Stemline Therapeutics reports second quarter 2016 financial results and highlights recent clinical progress .Q2 earnings per share view $-0.55 -- Thomson Reuters I/B/E/S.  Full Article